Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
TOKYO, July 17, 2026 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted for evaluation a marketing authorization application (MAA) for its in-house-discovered and developed orexin receptor antagonist lemborexant (generic
More